+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

PARP Inhibitor Biomarkers - Global Strategic Business Report

  • PDF Icon

    Report

  • 278 Pages
  • April 2025
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 6071797
The global market for PARP Inhibitor Biomarkers was estimated at US$951.7 Million in 2024 and is projected to reach US$1.5 Billion by 2030, growing at a CAGR of 7.6% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the PARP Inhibitor Biomarkers market.

Global PARP Inhibitor Biomarkers Market - Key Trends & Drivers Summarized

Why Is the PARP Inhibitor Biomarkers Market Gaining Momentum?

The PARP inhibitor biomarkers market is expanding as the role of precision medicine in oncology continues to grow. PARP (poly ADP-ribose polymerase) inhibitors are a class of targeted therapies used in the treatment of cancers such as ovarian, breast, prostate, and pancreatic cancer. The need for predictive biomarkers to identify patients who will respond to PARP inhibitors is driving advancements in companion diagnostics and genomic testing.

Additionally, the increasing availability of next-generation sequencing (NGS) and liquid biopsy technologies is enabling more precise biomarker identification, improving treatment selection and patient outcomes. The expansion of clinical trials exploring new applications of PARP inhibitors is further fueling market demand.

How Are Genomic Testing and Companion Diagnostics Transforming PARP Inhibitor Biomarker Identification?

The integration of genomic testing into cancer care is revolutionizing PARP inhibitor biomarker discovery. BRCA1/2 mutation testing, homologous recombination deficiency (HRD) assays, and loss-of-heterozygosity (LOH) analysis are becoming standard tests for predicting PARP inhibitor efficacy. These biomarkers help oncologists tailor treatment plans, improving therapeutic success rates.

Companion diagnostics are also playing a crucial role, with regulatory agencies approving biomarker-based tests alongside PARP inhibitor therapies. AI-driven bioinformatics tools are further refining biomarker identification, enhancing accuracy and clinical decision-making.

Is the Expansion of PARP Inhibitor Applications Driving Market Growth?

The growing application of PARP inhibitors beyond ovarian and breast cancer is expanding the market for PARP inhibitor biomarkers. Research is exploring their use in lung, pancreatic, and colorectal cancers, increasing the demand for biomarker testing to guide patient selection.

Additionally, the rise of combination therapies involving PARP inhibitors and immune checkpoint inhibitors is driving biomarker innovation. Scientists are developing predictive tests that assess tumor microenvironments and immune response, leading to more personalized treatment strategies.

What’s Driving the Growth of the PARP Inhibitor Biomarkers Market?

The growth in the PARP inhibitor biomarkers market is driven by the increasing adoption of precision oncology, advancements in genomic testing, and the expansion of PARP inhibitor applications. The rising demand for companion diagnostics and AI-powered biomarker identification is further accelerating market growth.

Additionally, regulatory approvals for biomarker-driven therapies, the growing investment in cancer research, and the integration of NGS and liquid biopsy technologies are fueling innovation. As personalized cancer treatment continues to evolve, the demand for PARP inhibitor biomarkers is expected to rise significantly.

Report Scope

The report analyzes the PARP Inhibitor Biomarkers market, presented in terms of market value (US$ Thousand). The analysis covers the key segments and geographic regions outlined below.

Segments: Product Type (PARP Inhibitor Biomarker Kits, PARP Inhibitor Biomarker Assays); Application (Breast Cancer Application, Ovarian Cancer Application, Other Applications)

Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the PARP Inhibitor Biomarker Kits segment, which is expected to reach US$1.0 Billion by 2030 with a CAGR of a 8.8%. The PARP Inhibitor Biomarker Assays segment is also set to grow at 5.3% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, estimated at $259.3 Million in 2024, and China, forecasted to grow at an impressive 12.1% CAGR to reach $317.4 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global PARP Inhibitor Biomarkers Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global PARP Inhibitor Biomarkers Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global PARP Inhibitor Biomarkers Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of players such as Agilent Technologies, Inc., Ambry Genetics, Amoy Diagnostics Co., Ltd., AstraZeneca, Bio-Rad Laboratories, Inc. and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 44 Featured):

  • Agilent Technologies, Inc.
  • Ambry Genetics
  • Amoy Diagnostics Co., Ltd.
  • AstraZeneca
  • Bio-Rad Laboratories, Inc.
  • CENTOGENE N.V.
  • Exagen Inc.
  • F. Hoffmann-La Roche AG
  • Genway Biotech, Inc.
  • GlaxoSmithKline (GSK)
  • Illumina, Inc.
  • Invitae Corporation
  • Merck & Co., Inc.
  • Myriad Genetics, Inc.
  • NeoGenomics Laboratories
  • Pfizer Inc.
  • QIAGEN
  • Siemens Healthcare GmbH
  • Svar Life Science AB
  • Thermo Fisher Scientific Inc.

Tariff Impact Analysis: Key Insights for 2025

Global tariff negotiations across 180+ countries are reshaping supply chains, costs, and competitiveness. This report reflects the latest developments as of April 2025 and incorporates forward-looking insights into the market outlook.

The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.

What’s Included in This Edition:

  • Tariff-adjusted market forecasts by region and segment
  • Analysis of cost and supply chain implications by sourcing and trade exposure
  • Strategic insights into geographic shifts

Buyers receive a free July 2025 update with:

  • Finalized tariff impacts and new trade agreement effects
  • Updated projections reflecting global sourcing and cost shifts
  • Expanded country-specific coverage across the industry

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • Tariff Impact on Global Supply Chain Patterns
  • PARP Inhibitor Biomarkers - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Advancements in Precision Oncology Throw Spotlight on Biomarker-Guided PARP Inhibitor Therapies
  • Growing Clinical Validation of BRCA and HRD Biomarkers Accelerates Diagnostic Adoption
  • FDA Approvals and Expanded Indications Propel Growth in Companion Diagnostics
  • Increasing Use of Genomic Testing in Ovarian, Breast, and Prostate Cancer Supports Market Expansion
  • Rising Investment in Targeted Cancer Therapies Strengthens Business Case for Biomarker Discovery
  • Integration of Next-Generation Sequencing Enhances Detection Accuracy and Clinical Utility
  • Reimbursement Expansion for Molecular Diagnostic Panels Drives Adoption in Oncology Workflows
  • Strategic Collaborations Between Pharma and Diagnostic Firms Accelerate Commercialization
  • Growing Role of Tumor Profiling in Therapy Selection Expands Demand for Companion Biomarkers
  • Emergence of Liquid Biopsy-Based Assays Opens Up Non-Invasive Testing Opportunities
  • Academic Research and Clinical Trials Fuel Development of Novel Predictive Biomarkers
  • Global Push for Personalized Cancer Care Supports Inclusion of PARP Biomarkers in Guidelines
  • Integration with AI and Data Analytics Tools Improves Biomarker Interpretation and Treatment Decisions
  • Pharmaceutical Pipeline Expansion of PARP Inhibitors Creates Parallel Demand for Diagnostic Ecosystem
  • Regulatory Harmonization in Biomarker Validation Enhances Global Market Accessibility
4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World PARP Inhibitor Biomarkers Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for PARP Inhibitor Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for PARP Inhibitor Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for PARP Inhibitor Biomarker Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for PARP Inhibitor Biomarker Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for PARP Inhibitor Biomarker Kits by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for PARP Inhibitor Biomarker Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for PARP Inhibitor Biomarker Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for PARP Inhibitor Biomarker Assays by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Breast Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Breast Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Breast Cancer Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Ovarian Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Ovarian Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Ovarian Cancer Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
III. MARKET ANALYSIS
  • UNITED STATES
  • PARP Inhibitor Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 20: USA Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 21: USA Historic Review for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 22: USA 15-Year Perspective for PARP Inhibitor Biomarkers by Product Type - Percentage Breakdown of Value Sales for PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays for the Years 2015, 2025 & 2030
  • TABLE 23: USA Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 24: USA Historic Review for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 25: USA 15-Year Perspective for PARP Inhibitor Biomarkers by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Ovarian Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • CANADA
  • TABLE 26: Canada Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 27: Canada Historic Review for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 28: Canada 15-Year Perspective for PARP Inhibitor Biomarkers by Product Type - Percentage Breakdown of Value Sales for PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays for the Years 2015, 2025 & 2030
  • TABLE 29: Canada Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 30: Canada Historic Review for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 31: Canada 15-Year Perspective for PARP Inhibitor Biomarkers by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Ovarian Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • JAPAN
  • PARP Inhibitor Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 32: Japan Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 33: Japan Historic Review for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 34: Japan 15-Year Perspective for PARP Inhibitor Biomarkers by Product Type - Percentage Breakdown of Value Sales for PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays for the Years 2015, 2025 & 2030
  • TABLE 35: Japan Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 36: Japan Historic Review for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 37: Japan 15-Year Perspective for PARP Inhibitor Biomarkers by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Ovarian Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • CHINA
  • PARP Inhibitor Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 38: China Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 39: China Historic Review for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 40: China 15-Year Perspective for PARP Inhibitor Biomarkers by Product Type - Percentage Breakdown of Value Sales for PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays for the Years 2015, 2025 & 2030
  • TABLE 41: China Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 42: China Historic Review for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 43: China 15-Year Perspective for PARP Inhibitor Biomarkers by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Ovarian Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • EUROPE
  • PARP Inhibitor Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 44: Europe Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 45: Europe Historic Review for PARP Inhibitor Biomarkers by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 46: Europe 15-Year Perspective for PARP Inhibitor Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 47: Europe Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Europe Historic Review for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 49: Europe 15-Year Perspective for PARP Inhibitor Biomarkers by Product Type - Percentage Breakdown of Value Sales for PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays for the Years 2015, 2025 & 2030
  • TABLE 50: Europe Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Europe Historic Review for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 52: Europe 15-Year Perspective for PARP Inhibitor Biomarkers by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Ovarian Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • FRANCE
  • PARP Inhibitor Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 53: France Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 54: France Historic Review for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 55: France 15-Year Perspective for PARP Inhibitor Biomarkers by Product Type - Percentage Breakdown of Value Sales for PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays for the Years 2015, 2025 & 2030
  • TABLE 56: France Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 57: France Historic Review for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 58: France 15-Year Perspective for PARP Inhibitor Biomarkers by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Ovarian Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • GERMANY
  • PARP Inhibitor Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 59: Germany Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Germany Historic Review for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 61: Germany 15-Year Perspective for PARP Inhibitor Biomarkers by Product Type - Percentage Breakdown of Value Sales for PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays for the Years 2015, 2025 & 2030
  • TABLE 62: Germany Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Germany Historic Review for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 64: Germany 15-Year Perspective for PARP Inhibitor Biomarkers by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Ovarian Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • ITALY
  • TABLE 65: Italy Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Italy Historic Review for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 67: Italy 15-Year Perspective for PARP Inhibitor Biomarkers by Product Type - Percentage Breakdown of Value Sales for PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays for the Years 2015, 2025 & 2030
  • TABLE 68: Italy Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Italy Historic Review for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 70: Italy 15-Year Perspective for PARP Inhibitor Biomarkers by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Ovarian Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
  • PARP Inhibitor Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 71: UK Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 72: UK Historic Review for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 73: UK 15-Year Perspective for PARP Inhibitor Biomarkers by Product Type - Percentage Breakdown of Value Sales for PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays for the Years 2015, 2025 & 2030
  • TABLE 74: UK Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 75: UK Historic Review for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 76: UK 15-Year Perspective for PARP Inhibitor Biomarkers by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Ovarian Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • SPAIN
  • TABLE 77: Spain Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Spain Historic Review for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 79: Spain 15-Year Perspective for PARP Inhibitor Biomarkers by Product Type - Percentage Breakdown of Value Sales for PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays for the Years 2015, 2025 & 2030
  • TABLE 80: Spain Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Spain Historic Review for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 82: Spain 15-Year Perspective for PARP Inhibitor Biomarkers by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Ovarian Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • RUSSIA
  • TABLE 83: Russia Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Russia Historic Review for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 85: Russia 15-Year Perspective for PARP Inhibitor Biomarkers by Product Type - Percentage Breakdown of Value Sales for PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays for the Years 2015, 2025 & 2030
  • TABLE 86: Russia Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Russia Historic Review for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 88: Russia 15-Year Perspective for PARP Inhibitor Biomarkers by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Ovarian Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • REST OF EUROPE
  • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Rest of Europe Historic Review for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 91: Rest of Europe 15-Year Perspective for PARP Inhibitor Biomarkers by Product Type - Percentage Breakdown of Value Sales for PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays for the Years 2015, 2025 & 2030
  • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Rest of Europe Historic Review for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 94: Rest of Europe 15-Year Perspective for PARP Inhibitor Biomarkers by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Ovarian Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
  • PARP Inhibitor Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 96: Asia-Pacific Historic Review for PARP Inhibitor Biomarkers by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 97: Asia-Pacific 15-Year Perspective for PARP Inhibitor Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Asia-Pacific Historic Review for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 100: Asia-Pacific 15-Year Perspective for PARP Inhibitor Biomarkers by Product Type - Percentage Breakdown of Value Sales for PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays for the Years 2015, 2025 & 2030
  • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Asia-Pacific Historic Review for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 103: Asia-Pacific 15-Year Perspective for PARP Inhibitor Biomarkers by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Ovarian Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • AUSTRALIA
  • PARP Inhibitor Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • INDIA
  • PARP Inhibitor Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • SOUTH KOREA
  • REST OF ASIA-PACIFIC
  • LATIN AMERICA
  • PARP Inhibitor Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • ARGENTINA
  • BRAZIL
  • MEXICO
  • REST OF LATIN AMERICA
  • MIDDLE EAST
  • PARP Inhibitor Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • IRAN
  • ISRAEL
  • SAUDI ARABIA
  • UNITED ARAB EMIRATES
  • REST OF MIDDLE EAST
  • AFRICA
  • PARP Inhibitor Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Agilent Technologies, Inc.
  • Ambry Genetics
  • Amoy Diagnostics Co., Ltd.
  • AstraZeneca
  • Bio-Rad Laboratories, Inc.
  • CENTOGENE N.V.
  • Exagen Inc.
  • F. Hoffmann-La Roche AG
  • Genway Biotech, Inc.
  • GlaxoSmithKline (GSK)
  • Illumina, Inc.
  • Invitae Corporation
  • Merck & Co., Inc.
  • Myriad Genetics, Inc.
  • NeoGenomics Laboratories
  • Pfizer Inc.
  • QIAGEN
  • Siemens Healthcare GmbH
  • Svar Life Science AB
  • Thermo Fisher Scientific Inc.

Table Information